

Session 3: Engagement with Stakeholders

Academia Info Day



Why is it important for EMA to engage with stakeholders?

 To optimise the Agency's public service role in improving human and animal health by systematically integrating multi-stakeholder engagement by design into EMA's key activities and strategic priorities.

EMA engages with stakeholders to:

- ensure that EMA decisions are well informed, meet stakeholders' needs and reach them
- harness the widest expertise available
- raise awareness and understanding of EMA's evolving role and its work
- reinforce confidence and trust in the scientific and regulatory outcomes and in the EU system



Who are our stakeholders?

- Over time EMA developed frameworks formalising its interaction with:
 - Patients and consumers (2005)
 - Healthcare professionals and learned societies (2011)
 - Industry and EU trade organisations (2015)
 - Academia (2017)

Other relevant stakeholders

- Media
- HTA bodies and payers
- Ethics committees
- CROs
- Tech developers

Multi-stakeholder engagement by design

- Develop and implement a **streamlined and coordinated approach** to multi-stakeholder engagement at EMA to support implementation of EMA's strategic priorities and new legislation
- Support cross-Agency implementation of EMAN and RSS strategies to 2025 and multi-stakeholder engagement in new areas under EMA's Extended Mandate
- Support targeted or multi-stakeholders **training and education on EMA activities** in cooperation with EMA partners (EC, EU Network, ICH)
- Monitor, evaluate and report on multi-stakeholder engagement to ensure optimal public service,
 continuous improvement and transparency



Do we also interact with other European and international agencies?

EMA **partners** – with whom there are operational links – encompass:

Within the European regulatory network:


- National competent authorities
- European Commission
- European Parliament
- Other European Institutions

European Centre for Disease Prevention and Control (ECDC); European Food Safety Authority (EFSA); European Chemicals Agency (ECHA); European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); European Environment Agency (EEA)

International (organisations) partners:

- World Health Organisation (WHO)
- US Food and Drug Administration (FDA)
- Health Canada
- Japanese regulatory authorities (MHLW and PMDA)

How do we engage our stakeholders in our work?



Impact: examples of how stakeholders influence our work


- Medicine specific
- Strategic EMAN and RSS strategies to 2025
- Policy wise transparency of clinical trials; handling of competing interests
- Operational CTIS; ePI and template review of product information
- Crisis management



Stakeholder engagement during crisis management

In crisis, engagement became more important than ever

- Voices of civil society in scientific committees
- Patients and HCPs on EMA COVID-19 Taskforce (ETF)
- COVID-19 communications review: key messages, channels
- Patient and healthcare professional organisations disseminated EMA's COVID-19 communications, advice
- Regular updates in PCWP/HCPWP meetings
- EMA public stakeholder meetings: Dec 2020, Jan/Mar/Nov 2021





Added value and impact during crisis management

- Gather critical input into crisis-related activities in COVID-19 context
- Gain insight into concerns of specific groups of patients and healthcare professionals e.g. about vaccination
- Support specific information needs, e.g. discussions on vaccines, associated social challenges, hesitancy, review of safety communications to the public...
- Channel public health messages to communities of patients and citizens more effectively
- Reinforce legitimacy of actions, trust in scientific outcomes and EU system





Any questions?

Further information

Ivana.Silva@ema.europa.eu

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Telephone +31 (0)88 781 6000

Send us a question Go to www.ema.europa.eu/contact

